Please find attached the disclosure.

Date: 17-08-2026 To To The General Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Mumbai - 400 051 Ref: BSE Scrip Code: 533259; NSE Symbol: HEALTHX Dear Sir/Madam, Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Transcript of Earnings Conference call for Q1 FY27 Ref: Our letter dated 05.08.2026 for intimation of schedule of the Earnings Conference Call for Q1 FY’27. This is in furtherance to our letter dated August 5, 2026 intimating that a Earnings Conference Call with investors and analysts was scheduled to be held on 11th August, 2026 at 4.00 PM (IST) to discuss the performance for the quarter ended June 30, 2026 and updates of the Company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the transcript of the said call with the Investors and analysts. Please also find herein below the link of the transcript of the said call that has been uploaded on the website of the Company. https://healthxplatform.com/Pdf/HXPL_Q1_FY27_Earnings_Call_Transcript.pdf You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Health X Platform Limited (formerly known as Sastasundar Ventures Limited) Pratap Singh Company Secretary & Compliance Officer M. No.: ACS-24081 “Health X Platform Limited Q1 & FY27 Earning Conference Call” August 11, 2026 MANAGEMENT: MR. B.L. MITTAL – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – HEALTH X PLATFORM LIMITED MR. LOKESH AGARWAL – CHIEF FINANCIAL OFFICER – HEALTH X PLATFORM LIMITED MANAGEMENT: MS. SOUMYA – GO INDIA ADVISORS Page 1 of 18 Health X Platform Limited August 11, 2026 Moderator: Ladies and gentlemen, good day and welcome to Health X Platform Limited Q1 and FY27 Earning Conference Call hosted by Go India Advisors. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Soumya from Go India Advisors. Thank you, and over to you Soumya. Soumya: Hi everyone, I welcome you all to Health X Platform Limited Q1 FY27 Earnings Con Call. Please note that discussions on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks pertaining to the business. We have on call today Mr. B.L. Mittal, the Managing Director and CEO, and Mr. Lokesh Agarwal, the CFO. I now request the management to proceed with the opening remarks. Post that, we will open the floor for Q&A. Thank you and over to you sir. B.L. Mittal: Good afternoon, friends. I am B.L. Mittal. Welcome to the Health X Platform Limited Q1 FY27 Earnings and Business Update Call. We sincerely appreciate your continued trust and support as we build Health X into a technology-led, capital-efficient healthcare platform with a clear objective of making healthcare more affordable, accessible, and trustworthy across India. Q1 FY27 has been an encouraging start to the year for us. The initiatives that we have invested in during the previous year across RetailerShakti, SastaSundar, geographical expansion, fulfilment infrastructure, technology, and JITO are now beginning to translate into stronger revenue momentum while we continue to work towards improving the underlying economics of the business, building scale with a strong operating foundation. The strength of our platform today is reflected in the scale we have built. We currently serve approximately 75,000 retail pharmacies with more than 50,000 SKUs sourced from over 1,000 vendors, supported by more than 350 health buddies and 3,500 employees. Importantly, more than 95% of our purchases are sourced directly from pharmaceutical companies without paying any purchase rights, while our purchase return remains below 1%. This gives us a strong sourcing and availability advantage as we continue to scale. RetailerShakti and SastaSundar both are driving growth now. Our revenue momentum has achieved meaningfully, led by our two core platforms. RetailerShakti grew 48% Y-o-Y, continuing to remain our principal growth engine. While SastaSundar grew 44% Y-o-Y, reflecting a strong B2C business. The quality of this growth is also encouraging. Within Retailer Shakti, 69.4% of business comes from orders above 2,500 and 42.4% from orders above 5,000, indicating that retailers are increasingly consolidating a meaningful share of their procurement requirements on our platform. This also eliminates the focus on certain customers because the sales are widespread of in thousands of customers. Page 2 of 18 Health X Platform Limited August 11, 2026 Similarly, 69.2% of SastaSundar orders are above 1,000, highlighting a healthy consumer basket size, and it also reflects that 30.8% of our orders are going below 1,000 that shows us the capability to serve even the smallest order. Together these platforms provide us with a strong base to deepen customer engagement and build a larger healthcare ecosystem. We are expanding beyond our existing markets, a part of our key strategy is to replicate this model across geographies. Building on our existing West Bengal infrastructure, we have expanded into Odisha, Bihar, and Jharkhand, while strengthening our northern operations through our Noida infrastructure. We have already deployed sales team and established the logistics and fulfilment capabilities required to penetrate these markets. The early response reinforce our confidence in this strategy. Importantly, our business is not dependent only on large metropolitan markets. Approximately 67% of RetailerShakti business and 78% of SastaSundar business comes from tier 2 and tier 3 markets. This reinforces our philosophy of inclusive healthcare infrastructure in India, which the India needs and we provide across geographies, across income level. This demonstrates the scalability of our model and the significant opportunity available in underserved markets where accessibility, affordability, and reliability availability remain important needs. Our new initiative JITO, which is creating another growth opportunity. That is another strategic initiative, a JITO private label, through which we aim to make quality healthcare significantly more affordable by offering medicines at prices up to 60% lower than leading branded alternatives. We see JITO as an opportunity to simultaneously improve affordability for customers and create an additional margin opportunity for the platform. At this stage, our focus remains on building the right distribution network, establishing customer acceptance, and scaling the business in a disciplined manner. We are investing ahead of scale while improving economics on profitability. EBITDA stood at INR14.9 crores during the quarter. As we continue to invest on team and in technology-led capabilities across procurement, fulfilment, inventory management, and customer engagement. I would like to reiterate that almost all our revenue is contribution margin positive revenue. We have consistently maintained that technology investments need to be made ahead of scale, but capital deployment must ultimately be supported by sound economics. Our objective is, therefore, to continue investing in capabilities that can provide productivity and customer experience, while progressively moving the platform towards stronger profitability and capital efficiency. Our PAT stood at INR2 crores, reflecting the improving underlying economics of the business. Technology and fulfilment are also key enablers. Technology rema [Showing first 8,000 characters — download PDF for full document]